The in vivo data on THCV and CBD thus represent highly relevant and original contributions, showcasing their potential to offer a more holistic approach to T2DM management compared to the more singular action of synthetic SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.